natgillin/translations-raw huggingface dataset:
There was no meaningful interaction observed when verapamil was given 2 hours after dabigatran etexilate (increased of Cmax by about 10 % and AUC by about 20 %).
Ob jemanju verapamila 2 uri po dabigatran eteksilatu ni bilo opaženih pomembnih interakcij (Cmax se je povečala za približno 10% in AUC za približno 20%).
There was no meaningful interaction observed when verapamil was given 2 hours after dabigatran etexilate (increased of Cmax by about 10 % and AUC by about 20 %).
Če so verapamil dajali 2 uri po dabigatran eteksilatu, ni bilo večje interakcije (Cmax se je povečala za približno 10 %, AUC pa za približno 20 %).
There was no pharmacokinetic drug-drug interaction between apremilast and methotrexate in psoriatic arthritis patients.
Pri bolnikih s psoriatičnim artritisom med apremilastom in metotreksatom ni bilo farmakokinetičnih interakcij.
There was no pharmacokinetic drug-drug interaction between apremilast and oral contraceptives containing ethinyl estradiol and norgestimate.
Med apremilastom in peroralnimi kontracepcijskimi sredstvi, ki vsebujejo etinilestradiol in norgestimat, ni bilo farmakokinetičnih interakcij.
There was no protein binding displacement between enzalutamide and other highly bound drugs (warfarin, ibuprofen and salicylic acid) in vitro.
In vitro ni prišlo do izpodrivanja pri vezavi na beljakovine med enzalutamidom in drugimi zdravili, ki se močno vežejo (varfarin, ibuprofen in salicilna kislina).
There was no relevant accumulation of rivastigmine or the metabolite NAP226-90 in plasma in patients with Alzheimer’s disease, except that plasma levels were higher on the second day of transdermal patch therapy than on the first.
Do pomembnega kopičenja rivastigmina ali presnovka NAP226-90 v plazmi bolnikov z Alzheimerjevo boleznijo ni prišlo, razen koncentracij v plazmi, ki so bile drugi dan zdravljenja s transdermalnim obližem višje kot prvi dan.
There was no relevant change over the 6-12 months treatment period.
V 6- do 12- mesečnem obdobju zdravljenja ni bilo pomembnih sprememb.
There was no relevant difference in adverse event frequencies between patients above and below the age of 2 years, however this is based on only 21 children less than 2 years including 6 patients between 3 months to 1 year of age.
Ni bilo pomembne razlike v pogostnosti neželenih učinkov med bolniki, starejšimi in mlajšimi od 2 let, vendar ta ugotovitev temelji le na 21 bolnikih, mlajših od 2 let, vključno s 6 bolniki, starimi od 3 mesecev do 1 leta.
There was no relevant difference in adverse event frequencies between patients above and below the age of 2 years, however this is based on only 21 children less than 2 years, including 6 patients between 3 months to 1 year of age.
Ni bilo pomembne razlike v pogostnosti neželenih učinkov med bolniki, starejšimi in mlajšimi od 2 let, vendar ta ugotovitev temelji le na 21 bolnikih, mlajših od 2 let, vključno s 6 bolniki, starimi od 3 mesecev do 1 leta.
There was no relevant impact on abdominal symptoms in either study (p=0.256 and p=0.916, Kodiac 4 and 5, respectively).
Ne v eni ne v drugi študiji ni bilo pomembnega vpliva na trebušne simptome (Kodiac 4 p = 0,256 in Kodiac 5 p = 0,916).
There was no significant difference in percentage of patients with cardiac dysfunction at first assessment (13% for Ferriprox vs.
Znatna razlika v deležu pacientov s kardialno disfunkcijo pri prvem ocenjevanju ni bila opažena (13 % pri Ferriproxu proti
There was no significant difference in probability of bone fracture (5.1% placebo, 5.1% salmeterol, 5.4% FP and 6.3% salmeterol/fluticasone propionate; hazard ratio for salmeterol/fluticasone propionate vs placebo: 1.22, 95% CI: 0.87 to 1.72, p=0.248.
Statistično značilne razlike v verjetnosti zloma kosti niso opazili (5,1 % placebo, 5,1 % salmeterol, 5,4 % FP in 6,3 % salmeterol/flutikazonpropionat; razmerje ogroženosti za salmeterol/flutikazonpropionat v primerjavi s placebom je bilo: 1,22; 95-odstotni IZ: 0,87 do 1,72, p = 0,248).
There was no statistically significant difference between nivolumab and chemotherapy in the preliminary OS analysis that was not adjusted for the potentially confounding effects of subsequent therapy.
Pri preliminarni analizi celokupnega preživetja, ki ni bila prilagojena za potencialno moteče učinke nadaljnjega zdravljenja, ni bilo statistično pomembne razlike med nivolumabom in kemoterapijo.
There was no statistically significant difference between pembrolizumab and chemotherapy in the preliminary OS analysis that was not adjusted for the potentially confounding effects of crossover.
Preliminarna analiza celokupnega preživetja (nekorigirana za možne moteče vplive terapevtskega prehoda) ni pokazala statistično značilne razlike med pembrolizumabom in kemoterapijo.
There was no statistically significant difference in discontinuation due to adverse events between duloxetine and placebo groups during the 10 week acute treatment phase.
Med skupino z duloksetinom in skupino s placebom v 10- tedenski fazi akutnega zdravljenja ni bilo statistično pomembne razlike v prekinitvi zdravljenja zaradi neželenih učinkov.
There was no statistically significant difference in overall survival between the treatment groups at the time of the primary efficacy analysis (HR=0.73; 95%CI: 0.50, 1.07, p=0.1032).
Ni bilo statistično značilne razlike v celotnem preživetju med skupinama z različnima zdravljenjema v času analize primarne učinkovitosti (HR (hazard ratio; razmerje tveganja)=0,73; 95 % IZ: 0,50; 1,07, p=0,1032).
There was no statistically significant difference in the rates of fatal bleeding (1.1% in the clopidogrel + ASA group and 0.7% in the placebo +ASA group) and haemorrhagic stroke (0.8% and 0.6%, respectively) between groups.
Med skupinama ni bilo statistično značilne razlike v deležih krvavitev s smrtnim izidom (1,1 % klopidogrel + acetilsalicilna kislina, 0,7 % placebo + acetilsalicilna kislina) in hemoragičnih možganskih kapi (0,8 % v prim. z 0,6 %).
There was no statistically significant difference in the rates of fatal bleeding (1.1% in the clopidogrel + ASA group and 0.7% in the placebo +ASA group) and haemorrhagic stroke (0.8% and 0.6%, respectively) between groups.
Med skupinama ni bilo statistično značilne razlike v deležih krvavitev s smrtnim izidom (1,1 % klopidogrel + ASA, 0,7 % placebo + ASA) in hemoragičnih možganskih kapi (0,8 % v prim. z 0,6 %).
There was no statistically significant effect of tadalafil on levonorgestrel which suggests the effect of ethinylestradiol is due to inhibition of gut sulphation by tadalafil.
Tadalafil ni imel pomembnega učinka na levonorgestrel, kar kaže, da je do učinka na etinilestradiol prišlo zato, ker tadalafil zavira sulfation v prebavilih.
There was no treatment-related effect on embryo- fetal development.
Z uporabo zdravila povezanih učinkov na razvoj zarodkov ali plodov niso ugotovili.
There was no tumorigenic response in mice of either sex.
Pri miših obeh spolov ni bilo tumorogenega odziva.
There was no tumorigenic response in mice of either sex.
Pri miših tumorigenega odziva ni bilo ne pri samicah ne pri samcih.
There was no tumourigenic response in mice of either sex.
Pri miših obeh spolov ni bilo tumorogenega odziva.
There was not any evidence of worsening of depression up to 60 weeks treatment with Taltz as assessed by the Quick Inventory of Depressive Symptomatology Self Report.
Dokazov o poslabšanju depresije pri zdravljenju z zdravilom Taltz, ki je trajalo do 60 tednov, glede na kratko lestvico depresivne simptomatologije za samoporočanje (Quick Inventory of Depressive Symptomatology Self Report) ni bilo.
There was one case of symptomatic LVD in the Perjeta and trastuzumab-treated group.
V skupini, zdravljeni z zdravilom Perjeta in trastuzumabom, je bil opažen en primer simptomatskega LVD.
There was one fatal case, although it was poorly documented.
En primer je bil smrten, vendar je slabo dokumentiran.
There was one Grade 4 TEAE.
Bil je en neželeni učinek stopnje 4, ki se je pojavil med zdravljenjem.
There was significant improvement in DLQI scores in the ustekinumab groups as compared with placebo at week 24, which was maintained through weeks 52 and 100.
V skupini, ki je prejemala ustekinumab, je bila po 24 tednih zdravljenja pomembno izboljšana tudi ocena dermatološkega indeksa kakovosti življenja (Dermatology Life Quality Index – DLQI), ki se je ohranila do 52. in do 100. tedna.
There was the reduction of relative risk of recurrent myocardial infarction by 35% compared to treatment with unfractionated heparin (p <0.001).
Ob tem času je bilo relativno tveganje za ponovni miokardni infarkt za 35 % manjše kot pri nefrakcioniranem heparinu (p < 0,001).
There was up to about 2.5-fold increase in AUC in subjects with hepatic impairment compared to healthy subjects.
Pri preiskovancih z jetrno okvaro se je povečal AUC za približno 2,5-krat v primerjavi z zdravimi preiskovanci.
There were 0.6 % and 0 % of patients with hypotension and 2.8 % and 3.1 % of patients with dizziness as adverse reactions reported in the combination and monotherapy groups, respectively
V skupini, ki je prejemala kombinacijo učinkovin so pri 0,6 % bolnikov poročali o pojavu hipotenzije in pri 2,8 % bolnikov o pojavu omotice.
There were 10 new virologic failures between the Week 48 primary analysis and Week 96 (3 patients with baseline viral load ≤ 100,000 copies/mL and 7 patients with baseline viral load > 100,000 copies/mL).
Med primarno analizo v 48. tednu in 96. tednom se je pojavilo 10 novih viroloških neuspehov (3 bolniki z začetno virusno obremenitvijo ≤ 100.000 kopij/ml in 7 bolnikov z začetno virusno obremenitvijo > 100.000 kopij/ml).
There were 15 patients who received imatinib and no other second-generation TKI who met these criteria.
15 bolnikov, ki so izpolnjevali te kriterije, je prejemalo imatinib in nobenega drugega TKI druge generacije.
There were 17 new virologic failures between the week 48 primary analysis and week 96 (6 patients with baseline viral load ≤ 100,000 copies/mL and 11 patients with baseline viral load > 100,000 copies/mL).
Med primarno analizo v 48. tednu in 96. tednom se je pojavilo 17 novih viroloških neuspehov (6 bolnikov z začetno virusno obremenitvijo ≤ 100.000 kopij/ml in 11 bolnikov z začetno virusno obremenitvijo > 100.000 kopij/ml).
There were 2 primary endpoints: proportion of patients with a rescue-free laxation within 4 hours of the first dose of study medicinal product and proportion of patients with a rescue-free laxation within 4 hours after at least 2 of the first 4 doses of medicinal product.
Primarni končni točki sta bili dve: delež bolnikov z iztrebljanjem brez rešilnega odvajala v 4 urah po prvem odmerku preiskovanega zdravila in delež bolnikov z iztrebljanjem brez rešilnega odvajala v 4 urah po vsaj 2 od prvih 4 odmerkov zdravila.
There were 23 patients (4.4%) with a QTc increase from baseline >60 msec.
Pri 23 bolnikih (4,4 %) je prišlo do podaljšanja intervala QTc za >60 ms od izhodiščne vrednosti.
There were 25 adolescents 13 girls and 12 boys, 9 aged 12 -14 years and 16 aged 15-17 years enrolled in study MEA115588.
Študija MEA115588 je vključila 25 mladostnikov: 13 deklet in 12 fantov, 9 v starosti od 12 do 14 let in 16 v starosti od 15 do 17 let.
There were 32 patients aged 6-12 years, 41 patients aged 13-17 years and 114 patients aged 18 years and older.
32 bolnikov je bilo starih med 6 in 12 let, 41 bolnikov je bilo starih med 13 in 17 let in 114 bolnikov je bilo starih 18 let ali več.
There were 5 complete responses and 32 partial responses for an ORR of 70% (95% CI: 56%, 82%).
Bilo je 5 popolnih in 32 delnih odzivov na 70 % ORR (95 % IZ: 56 %, 82 %).
There were 570 patients treated with Bosulif in this trial including CP CML patients previously treated with only one prior TKI (imatinib), CP CML patients previously treated with imatinib and at least 1 additional TKI (dasatinib and/or nilotinib), CML patients in accelerated or blast phase previously treated with at least one TKI (imatinib) and patients with Ph+ ALL previously treated with at least one TKI (imatinib).
V preskušanju je 570 bolnikov prejemalo zdravilo Bosulif; v to število so bili vključeni bolniki s KML v kronični fazi, ki so bili predhodno zdravljeni z enim TKI (imatinib), bolniki s KML v kronični fazi, ki so bili predhodno zdravljeni z imatinibom in vsaj še enim dodatnim TKI (dasatinib in/ali nilotinib), bolniki s KML v pospešeni ali blastni fazi, ki so bili predhodno zdravljeni z enim TKI (imatinib) in bolniki s Ph+ ALL, ki so bili predhodno zdravljeni z vsaj enim TKI (imatinib).
There were 5897 patients enrolled, representing 49 % of patients originally randomly assigned to receive dabigatran etexilate in RE-LY and 86 % of RELY-ABLE–eligible patients.
Podaljšek je zajel 5897 (49 %) bolnikov iz raziskave RE-LY, ki so bili že v njej naključno razvrščeni v skupino dabigatran eteksilata, oziroma 86 % bolnikov, ki so izpolnjevali merila za vključitev v raziskavo RELY-ABLE.
There were 7/317 patients (2%) in the emtricitabine/rilpivirine/tenofovir disoproxil fumarate arm and 6/152 patients (4%) in the Delayed Switch arm who permanently discontinued study drug due to a treatment-emergent adverse event (TEAE).
V kraku z emtricitabinom/rilpivirinom//dizoproksiltenofovirat fumaratom je bilo 7/317 bolnikov (2 %) in v kraku s kasnejšim prehodom 6/152 bolnikov (4 %), ki so se trajno prenehali zdraviti s študijskim zdravilom zaradi neželenega učinka, ki se je pojavil med zdravljenjem.
There were 7/317 patients (2%) in the Eviplera arm and 6/152 patients (4%) in the Delayed Switch arm who permanently discontinued study drug due to a treatment-emergent adverse events (TEAE).
V kraku z zdravilom Eviplera je bilo 7/317 bolnikov (2 %) in v kraku s kasnejšim prehodom 6/152 bolnikov (4 %), ki so se trajno prenehali zdraviti s študijskim zdravilom zaradi neželenega učinka, ki se je pojavil med zdravljenjem.
There were 77 subjects enrolled into the first study and 109 into the second.
V prvi študiji je bilo vključenih 77 oseb, v drugi pa 109.
There were 80 paediatric CAPS patients (2-17 years of age) included in the studies.
V študije je bilo vključenih 80 pediatričnih bolnikov s CAPS (starih 2-17 let).
There were 95 subjects from group 2 who continued on 5 mg/kg every 6 weeks.
95 preiskovancev iz 2. skupine je nadaljevalo zdravljenje z jemanjem odmerka 5 mg/kg na vsakih 6 tednov.
There were 952 patients with HER2-negative tumours, and a total of 115 patients whose tumour HER2 status was unconfirmed (no tumour sample, no assay result, or other reason).
952 bolnic je imelo HER2- negativne tumorje, pri 115 bolnicah pa HER2-status tumorja ni bil potrjen (ni bilo vzorca tumorja, ni bilo rezultata preizkusa ali zaradi drugih razlogov).
There were a few cases of subjects with delayed elimination.
V nekaj primerih je bil čas izločanja daljši.
There were a total of 385 subject exposures involving over 14,500 infusions of Cinryze in these studies.
Vsega skupaj je bilo v teh študijah 385 izpostavljenih bolnikov, ki so prejeli več kot 14.500 infuzij zdravila Cinryze.
There were a total of 397 patients consented and randomised to the study (199 patients on 12-month arm and 198 patients on 36-month arm), median age was 61 years (range 22 to 84 years).
V sodelovanje v študiji je privolilo skupaj 397 bolnikov, ki so jih randomizirali (199 bolnikov v skupino z 12-mesečnim zdravljenjem, 198 bolnikov pa v skupino s 36- mesečnim zdravljenjem), pri čemer je bila srednja vrednost starosti bolnikov 61 let (v okviru od 22 do 84 let).
There were also 1,238 patients with mild renal impairment, and 143 patients with moderate renal impairment on linagliptin.
Linagliptin je poleg tega jemalo tudi 1.238 bolnikov z blago in 143 z zmerno ledvično okvaro.
There were also reductions in patients’ symptoms, such as pain and inflammation, and improvements in vision.
Poleg tega so pri bolnikih opazili ublažitev simptomov, kot sta bolečina in vnetje, ter izboljšanje vida.
There were corresponding decreases in OFF time.
Čas ‘OFF’ (obdobje, ko učinki zdravil niso bili izraženi) se je ustrezno zmanjšal.
There were four main studies in 842 chronic renal failure patients and three main studies in 586 non- myeloid cancer patients receiving chemotherapy.
Izvedli so štiri glavne študije na 842 bolnikih s kronično ledvično odpovedjo in tri glavne študije na 586 bolnikih z nemielodnim rakom, ki so prejemali kemoterapijo.
There were higher rates of Grade 4 neutropenia (ANC
Pri ženskah so ugotovili 12 % pogostnost nevtropenije 4. stopnje (absolutno število nevtrofilcev (ANC)
There were higher rates of Grade 4 neutropenia (ANC < 0.5 x 109/l), 12% vs 5%, and thrombocytopenia (< 20 x 109/l), 9% vs 3%, in women vs men in the first cycle of therapy.
V prvem ciklu zdravljenja je bila pri ženskah opažena večja pojavnost nevtropenije stopnje 4 (absolutno število nevtrofilcev < 0,5 x 109/l), in sicer pri 12 % v primerjavi s 5 % pri moških ter trombocitopenije (< 20 x 109/l) pri 9 % v primerjavi s 3 % pri moških.
There were isolated reports of severe infusion reactions in clinical trials.
V kliničnih preskušanjih so poročali o posameznih primerih hude infuzijske reakcije.
There were more days without any apnoea under caffeine citrate treatment (3.0 days, versus 1.2 days for placebo; p=0.005); also, there was a higher percentage of patients with no apnoeas for > 8 days (caffeine 22% versus placebo 0%).
Pri zdravljenju s kofeinijevim citratom je bilo več dni brez vsakršne apneje (3,0 dni v primerjavi z 1,2 dni za placebo; p = 0,005); prav tako je bil večji odstotek bolnikov brez apnej za > 8 dni (kofein 22 % v primerjavi s placebom 0 %).
There were neither statistically significant nor clinically relevant differences in bevacizumab clearance in patients receiving Avastin monotherapy compared to patients receiving Avastin in combination with interferon alfa-2a, erlotinib or chemotherapies (IFL, 5-FU/LV, carboplatin/paclitaxel, capecitabine, doxorubicin or cisplatin/gemcitabine).
Pri bolnikih, ki so prejemali samostojno zdravljenje z zdravilom Avastin, v primerjavi z bolniki, ki so prejemali zdravilo Avastin v kombinaciji z interferonom alfa-2a, erlotinibom ali kemoterapijami (IFL, 5-FU/LV, karboplatin/paklitaksel, kapecitabin, doksorubicin ali cisplatin/gemcitabin), ni bilo statistično značilnih ali klinično pomembnih razlik v očistku bevacizumaba.
There were no accompanying clinical symptoms and the event resolved.
Spremljajočih kliničnih simptomov ni bilo in dogodek je izzvenel.
There were no adverse reactions in the low-dose animals in the presence or absence of anaesthesia, and no infusion-related reactions in the mid-dose group in the absence of anaesthesia.
V nizkoodmerni skupini živali ni bilo neželenih reakcij ne z anestezijo ne brez nje, v srednjeodmerni skupini pa ni bilo z infundiranjem povezanih reakcij brez anestezije.
There were no biologically relevant haematology differences or serum chemistry differences after the 14-day period.
Ni bilo biološko relevantnih hematoloških sprememb ali kemičnih sprememb seruma v obdobju po 14 dneh.
There were no cases of serotonin syndrome in the rasagiline clinical program in which 115 patients were exposed concomitantly to rasagiline and tricyclics and 141 patients were exposed to rasagiline and SSRIs/ SNRIs.
V kliničnem programu z rezagilinom, v katerem je bilo 115 bolnikov izpostavljenih hkrati razagilinu in triciklikom, 141 bolnikov pa je bilo izpostavljenih razagilinu in SSRI/SNRI, ni bilo primerov serotoninskega sindroma.
There were no clinical signs associated with unilateral vesicle formation within the epithelium of the tympanic membrane (also observed after six administrations, one week apart, of 1 tube per ear or 2 tubes per dog), unilateral mucosal ulceration in the lining of the middle ear cavity, or decrease in serum cortisol response below normal reference range in ACTH stimulation testing.
Ni bilo kliničnih znakov, povezanih z enostranskim nastajanjem veziklov v epiteliju membrane bobniča (tudi po šestih aplikacijah po eno tubo na uho oziroma dve na psa v razmiku enega tedna), enostransko ulceracijo sluznice srednjega ušesa ali zmanjšanjem odziva serumskega kortizola pod normalnim referenčnim razponom pri stimulacijskem testiranju ACTH.
There were no clinically important pharmacokinetic differences between patients with severe renal insufficiency and healthy subjects.
Farmakokinetika se pri bolnikih s hudo insuficienco ledvic in zdravih osebah ni klinično pomembno razlikovala.
There were no clinically important pharmacokinetic differences due to gender, race or body mass index (BMI) for raltegravir in adults.
Glede na spol, raso ali indeks telesne mase (ITM) pri odraslih niso ugotovili klinično pomembnih razlik v farmakokinetiki raltegravirja.
There were no clinically meaningful differences in the incidence of adverse events following treatment with Xiapex based on the severity of baseline erectile dysfunction or concomitant phosphodiesterase type 5 (PDE5) inhibitor use.
Klinično pomembnih razlik v incidenci neželenih učinkov po zdravljenju z zdravilom Xiapex na podlagi resnosti erektilne disfunkcije ob izhodišču ali sočasne uporabe zaviralca fosfodiesteraze tipa 5 (PDE5) ni bilo.
There were no clinically relevant changes from baseline in pain scores in either the methylnaltrexone bromide or placebo-treated patients.
Klinično pomembnih sprememb od izhodišča v seštevku po lestvici za bolečino ni bilo ne za bolnike, zdravljene z metilnaltreksonijevim bromidom, ne za bolnike, ki so dobivali placebo.
There were no clinically relevant changes in pain scores from baseline in either the methylnaltrexone bromide or placebo-treated patients.
Klinično pomembnih sprememb od izhodišča v seštevku po lestvici za bolečino ni bilo ne za bolnike, zdravljene z metilnaltreksonijevim bromidom, ne za bolnike, ki so dobivali placebo.
There were no clinically relevant changes in pain scores from baseline in either the methylnaltrexone bromide or placebo-treated patients.
Niti pri bolnikih, ki so prejemali metilnaltreksonijev bromid, niti pri tistih, ki so jemali placebo, ni bilo klinično pomembnih sprememb v lestvicah za ocenjevanje intenzivnosti bolečine.
There were no clinically relevant changes in the laboratory values or vital signs in either treatment group throughout the clinical trial.
Med klinično raziskavo se ne v eni ne v drugi skupini niso pojavile klinično pomembne spremembe laboratorijskih vrednosti ali vitalnih znakov.
There were no clinically relevant differences between naloxegol 12.5 mg, 25 mg, and placebo in average pain intensity, daily opioid dose or in opioid withdrawal scores over the 12-week study.
V 12-tedenski študiji niso ugotovili klinično pomembnih razlik v povprečni intenzivnosti bolečin, dnevnem odmerku opioidov ali oceni odtegnitve opioidov med 12,5 mg naloksegola, 25 mg naloksegola in placebom.
There were no clinically relevant differences in Cmax compared to healthy volunteers.
Pri vrednostih cmax ni prišlo so klinično pomembnih razlik v primerjavi z zdravimi prostovoljci.
There were no clinically relevant differences in systemic exposures between White, Black or Asian races.
Sistemska izpostavljenost se med belsko, črnsko in azijsko raso klinično ni pomembno razlikovala.
There were no clinically relevant differences in systemic exposures between White, Black or Asian races.
Sistemska izpostavljenost se med belsko, črnsko in azijsko raso ni klinično pomembno razlikovala.
There were no clinically relevant differences observed for the safety profile of ALIMTA plus cisplatin within the histology subgroups.
Za varnostni profil zdravila ALIMTA niso opazili nobenih klinično pomembnih razlik znotraj histoloških podskupin.
There were no clinically relevant differences observed for the safety profile of pemetrexed plus cisplatin within the histology subgroups.
Za varnostni profil pemetrekseda niso opazili nobenih klinično pomembnih razlik znotraj histoloških podskupin.
There were no clinically relevant differences observed for the safety profile of pemetrexed plus cisplatin within the histology subgroups.
Za varnostni profil pemetrekseda s cispaltinom niso opazili nobenih klinično pomembnih razlik znotraj histoloških podskupin.